← Back to Search

N/A

Plant-based patties group for Inflammation (FOOD-1 Trial)

N/A

Waitlist Available

Led By Abhinav Sharma, MD

Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline day 6-7-20-21

Awards & highlights

FOOD-1 Trial Summary

This trial looked at changes in a compound called TMAO after people ate either beef or plant-based burgers for a week.

FOOD-1 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline day 6-7-20-21

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline day 6-7-20-21

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline day 6-7-20-21 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in TMAO levels

Secondary outcome measures

Change in heart rate

Change in high-sensitivity c-reactive protein

Change in systolic and diastolic blood pressure

+1 more

Other outcome measures

Adherence of diet

Identification of study intervention

Tolerance of diet

FOOD-1 Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Plant-based pattiesExperimental Treatment1 Intervention

Participants will be randomized to group 2: plant-based burger which contains no animal products. The Plant-based burger selected is ''Beyond Burger" (https://www.beyondmeat.com/products/the-beyond-burger/ ). Participants will be given two patties per day.

Group II: Red meat pattiesActive Control1 Intervention

Participants will be randomized to group 1: Red meat, ''Costco Kirkland Signature 1/4 lb Ground Beef Patties'' (Beef burger). Participants will be given two patties per day.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor

442 Previous Clinical Trials

159,133 Total Patients Enrolled

4 Trials studying Inflammation

553 Patients Enrolled for Inflammation

João Pedro Ferreira, MDUNKNOWN

Abhinav Sharma, MDPrincipal InvestigatorMcGill University Health Centre/Research Institute of the McGill University Health Centre

3 Previous Clinical Trials

367 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still openings available to participants of this research?

"Affirmative, according to the information on clinicaltrials.gov this trial is still enrolling participants. Initially posted in November 2020 and last updated July 2022, it seeks 40 patients from one medical centre."

Answered by AI

What is the ceiling of participants for this experiment?

"Yes, the information on clinicaltrials.gov reveals that this experiment is presently recruiting patients. It was first posted on November 1st 2020 and most recently updated on July 26th 2022. The research requires 40 individuals to participate from a single medical facility."

Answered by AI

Is this research protocol open to participants aged 75 and above?

"As stated by the study's qualifying parameters, individuals aged between 25 and 65 are able to join this clinical trial."

Answered by AI

Would I be eligible to participate in this research study?

"Patients between the ages of 25 and 65 with evidence of inflammatory responses can apply to this medical trial. At present, roughly 40 participants are needed for enrolment."

Answered by AI

Recent research and studies

Cell MetabolismJournal

Trimethylamine-n-oxide, a Metabolite Associated with Atherosclerosis, Exhibits Complex Genetic and Dietary Regulation

Bennett, Brian J., Thomas Q. de Aguiar Vallim, Zeneng Wang, Diana M. Shih, Yonghong Meng, Jill Gregory, Hooman Allayee, et al.. 2013. “Trimethylamine-n-oxide, a Metabolite Associated with Atherosclerosis, Exhibits Complex Genetic and Dietary Regulation”. Cell Metabolism. Elsevier BV. doi:10.1016/j.cmet.2012.12.011.

CellJournal

Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis

Wang, Zeneng, Adam B. Roberts, Jennifer A. Buffa, Bruce S. Levison, Weifei Zhu, Elin Org, Xiaodong Gu, et al.. 2015. “Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis”. Cell. Elsevier BV. doi:10.1016/j.cell.2015.11.055.

European Heart JournalJournal

Gut Microbe-generated Metabolite Trimethylamine-n-oxide as Cardiovascular Risk Biomarker: A Systematic Review and Dose-response Meta-analysis

Schiattarella, Gabriele Giacomo, Anna Sannino, Evelina Toscano, Giuseppe Giugliano, Giuseppe Gargiulo, Anna Franzone, Bruno Trimarco, Giovanni Esposito, and Cinzia Perrino. 2017. “Gut Microbe-generated Metabolite Trimethylamine-n-oxide as Cardiovascular Risk Biomarker: A Systematic Review and Dose-response Meta-analysis”. European Heart Journal. Oxford University Press (OUP). doi:10.1093/eurheartj/ehx342.

Nature MedicineJournal